Background Individuals with electrocardiographically determined left ventricular hypertrophy (ECG LVH) are at risk of multiple cardiovascular disease (CVD) outcomes simultaneously. The study sought to characterise the competing incidences for subtypes of first CVD events or non-CVD death in those with and without ECG LVH.
Methods Participants in the Atherosclerosis Risk in Communities (ARIC) Study were included. ECG LVH was defined according to Sokolow–Lyon criteria. Competing Cox models were used to compare hazards for diverse outcomes within groups (eg, among those with ECG LVH) and for a given event between groups (ECG LVH vs no ECG LVH).
Results After 15 years, men with ECG LVH at baseline (N=383) had a cumulative incidence of first CVD events and non-CVD deaths of 29.2% and 6.1%, respectively (HR 4.86; 95% CI 3.04 to 7.77). In men without ECG LVH (N=6576) the incidence of any first CVD event and non-CVD death was 18.9% and 6.9%, respectively (HR 2.67; 2.39 to 2.98). Similar associations were observed in women (N=381 with and N=8187 without ECG LVH). Coronary heart disease (CHD) was the most common first event in men with ECG LVH (15.0%) and heart failure was the most common first event in women with ECG LVH (10.5%). After adjustment for risk factors including systolic blood pressure, any CVD event remained the most likely first event.
Conclusions Among middle-aged individuals with ECG LVH, the most likely first events are CHD in men and heart failure in women; these results may have implications for preventive approaches.
- Cardiovascular disease
- coronary heart disease
- heart failure
- left ventricular hypertrophy
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding This work was supported in part by grant R21 HL085375 from the National Heart, Lung, and Blood Institute. Dr. Desai is supported by T32 HL069771 from the National Heart, Lung, and Blood Institute.
Competing interests None.
Ethics approval Ethics approval was received from the institutional review board.
Provenance and peer review Not commissioned; externally peer reviewed.